摘要
PI3K-Akt-mTOR信号通路控制着众多在肿瘤发生发展中至关重要的细胞生物学过程,包括细胞凋亡、转录、翻译、代谢、血管新生以及细胞周期的调控。遗传学上的改变和生化条件引起的激活经常发生在恶变早期和肿瘤进展期,同时,信号通路激活程度也是肿瘤患者预后的重要指标。因此抑制该信号通路成为肿瘤预防和肿瘤靶向治疗的热点。对于该信号通路的各个激酶,均有多种抑制剂处于临床前和临床研究阶段。
PI3K-Akt-mTOR acts as an important controller in progress of tumorigenesis including apoptosis, transcription, translation, metabolism, angiogenesis and cell cycle. Genetic alterations and biochemical factors could occur in the early stage of neoplasm and tumor progress. To some degree, the activation of the signal transduction pathway could be served as a prognostic factor for tumor patients. Targeting PI3K-Akt-mTOR is becoming a hot area in tumor therapeutics. Many inhibitors against kinases involved in this signaling pathway are in preclinical and clinical trials. In our paper.
出处
《中国癌症杂志》
CAS
CSCD
2006年第12期1064-1070,共7页
China Oncology
基金
国家自然科学基金面上项目(No:30371645)
